COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) TREATMENT DRUGS MARKET ANALYSIS

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, by Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, and Others), by Dose Form (Solution and Tablet), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Nov 2020
Code : CMI4269
Pages :188
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Key Players

Major players operating in the global community-acquired bacterial pneumonia (CABP) treatment drugs market include Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.

COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) TREATMENT DRUGS MARKET ANALYSIS

Leading Companies

Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Report Snapshots

EXISTING CLIENTELE